Medtronic (MDT) Gets FDA Approval for Resolute Integrity DES
Tweet
Share
E-mailGet Alerts MDT Hot Sheet
Price: $79.19 +0.14%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3.4%
Revenue Growth %: -0.6%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3.4%
Revenue Growth %: -0.6%
Join SI Premium – FREE
Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD).
The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently powerful clinical performance across a broad spectrum of patients –– including those with diabetes, a common contributor to coronary artery disease that complicates treatment. The Resolute DES uses the same drug-and-polymer combination as the Resolute Integrity DES.
The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently powerful clinical performance across a broad spectrum of patients –– including those with diabetes, a common contributor to coronary artery disease that complicates treatment. The Resolute DES uses the same drug-and-polymer combination as the Resolute Integrity DES.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
- Flux Power (FLUX) Appoints Mark Leposky to its Board
- Medtronic, Inc. (MDT) PT Lowered to $88 at Baird
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
